Biotech · Private company
Cyclacel Pharmaceuticals, Inc.
Track this companyFree. Adds Cyclacel Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials181 recruiting or active
Pipeline programs26From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline26
- DecitabinePhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- SapacitabinePhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CYC140Phase 2 · Solid Tumor, Adult LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- fadraciclibPhase 2 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FadraciclibPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabinePhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- SapacitabinePhase 2 · Cutaneous T-cell Lymphoma (CTCL)ClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabine and decitabine (Part 1 - completed)Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabine and venetoclax (Part 2 - recruiting)Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Sapacitabine, Arm APhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Sapacitabine, Arm BPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Sapacitabine, Arm CPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Sapacitabine, Arm DPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabine, Arm EPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabine, Arm FPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- seliciclibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CYC065Phase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- CYC065Phase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- CYC065Phase 1 · Relapsed or Refractory Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CYC116Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CYC140Phase 1 · AML, AdultClinicalTrials.gov · fetched Nov 12, 2026
- FadraciclibPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabinePhase 1 · LeukemiasClinicalTrials.gov · fetched Nov 12, 2026
- sapacitabine and seliciclibPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · Relapsed or Refractory Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials18
- Absorption, Metabolism, and Excretion of CYC065 in Healthy Male SubjectsEARLY_PHASE1 · COMPLETED · started Mar 3, 2023ClinicalTrials.gov NCT05817890 · fetched Nov 12, 2026
- A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and LymphomaPHASE1_PHASE2 · UNKNOWN · started Apr 14, 2022ClinicalTrials.gov NCT05358379 · fetched Nov 12, 2026
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)PHASE1_PHASE2 · SUSPENDED · started Oct 22, 2021ClinicalTrials.gov NCT05168904 · fetched Nov 12, 2026
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and LymphomaPHASE1_PHASE2 · UNKNOWN · started Jul 12, 2021ClinicalTrials.gov NCT04983810 · fetched Nov 12, 2026
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSPHASE1 · COMPLETED · started Aug 2, 2019ClinicalTrials.gov NCT04017546 · fetched Nov 12, 2026
- A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDSPHASE1 · TERMINATED · started Mar 25, 2019ClinicalTrials.gov NCT03884829 · fetched Nov 12, 2026
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLPHASE1 · COMPLETED · started Jan 25, 2019ClinicalTrials.gov NCT03739554 · fetched Nov 12, 2026
- Olaparib + Sapacitabine in BRCA Mutant Breast CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 1, 2018ClinicalTrials.gov NCT03641755 · fetched Nov 12, 2026
- A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced CancersPHASE1 · COMPLETED · started Sep 28, 2015ClinicalTrials.gov NCT02552953 · fetched Nov 12, 2026
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaPHASE3 · COMPLETED · started Oct 1, 2011ClinicalTrials.gov NCT01303796 · fetched Nov 12, 2026
- Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)PHASE1_PHASE2 · UNKNOWN · started Jun 17, 2010ClinicalTrials.gov NCT01211457 · fetched Nov 12, 2026
- A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid TumorsPHASE1 · COMPLETED · started Apr 1, 2009ClinicalTrials.gov NCT00999401 · fetched Nov 12, 2026
- A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung CancerPHASE2 · TERMINATED · started Dec 1, 2008ClinicalTrials.gov NCT00885963 · fetched Nov 12, 2026
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly PatientsPHASE2 · COMPLETED · started Dec 1, 2007ClinicalTrials.gov NCT00590187 · fetched Nov 12, 2026
- A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started Jun 1, 2007ClinicalTrials.gov NCT00560716 · fetched Nov 12, 2026
- A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell LymphomaPHASE2 · TERMINATED · started Apr 1, 2007ClinicalTrials.gov NCT00476554 · fetched Nov 12, 2026
- Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung CancerPHASE2 · TERMINATED · started Aug 9, 2006ClinicalTrials.gov NCT00372073 · fetched Nov 12, 2026
- Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic SyndromesPHASE1 · COMPLETED · started Jan 1, 2006ClinicalTrials.gov NCT00380653 · fetched Nov 12, 2026